CTOR CITIUS ONCOLOGY, INC.
Price Chart
Executive Summary
Citius Oncology issued a press release highlighting Phase 1 data from an investigator-initiated study of LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab in recurrent/refractory gynecologic malignancies, presented at ASCO 2026. The data showed a 24% ORR (5/21 evaluable patients), a 33% ORR in checkpoint-inhibitor-pretreated endometrial cancer, and a median PFS of 20.5 months among the 48% of patients achieving clinical benefit. This is early-stage, investigator-initiated data not powered for efficacy, and LYMPHIR is not FDA-approved for this indication.
Actionable Insight
Early clinical signal in a new indication (gynecologic cancers) is encouraging but remains highly speculative given Phase 1 limitations and lack of FDA approval for solid tumors. Monitor for Phase 2 initiation and any partnership or financing updates. The stock's $74M market cap and prior poor historical performance on similar news suggest limited near-term catalyst impact.
Key Facts
- Phase 1 data presented May 30, 2026 at ASCO Annual Meeting (Abstract #2564) for LYMPHIR + pembrolizumab in recurrent/refractory gynecologic malignancies.
- 24% ORR among 21 efficacy-evaluable patients (5 partial responses); median duration of response not yet reached (median 21.1 months).
- 33% ORR in endometrial cancer patients previously treated with checkpoint inhibitors, including one ongoing response >3 years.
- 48% of evaluable patients (10/21) achieved clinical benefit; median PFS of 20.5 months in that subgroup.
- Safety: 1 reversible Grade 3 capillary leak syndrome at highest dose; no new safety signals; MTD not reached.
- LYMPHIR is not FDA-approved for gynecologic malignancies or any solid tumor; Phase 1 study not designed/powered for efficacy.
- A Phase 2 expansion study is being planned in gynecologic cancers.
- LYMPHIR was FDA-approved and launched in the U.S. in December 2025 for relapsed/refractory Stage I-III CTCL.
Financial Impact
No financial data provided in the filing. The press release contains no revenue, EPS, guidance, or deal figures.
Risk Factors
- Phase 1 data may not be predictive of larger or later-stage study results.
- LYMPHIR is not approved for gynecologic malignancies; regulatory path uncertain.
- Company faces going-concern risk and Nasdaq continued listing compliance concerns as noted in forward-looking statements.
- Heavily pre-treated patient population (median 5 prior therapies) limits generalizability.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-063530 |
| Document: ea0292903-8k_citius.htm | 0001213900-26-063530 |
| Document: 0001213900-26-063530-index-headers.html | 0001213900-26-063530 |
| Document: 0001213900-26-063530-index.html | 0001213900-26-063530 |
| Document: 0001213900-26-063530.txt | 0001213900-26-063530 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
7d ago
|
EFFECT
| $0.7786 awaiting T+1 | awaiting T+1 | — | $0.6640 (+14.72%) |
|
Jun 1, 2026
13d ago
|
8-K
| $0.7830 $0.7800 | ▼ −0.38% | ▲ +0.34% | $0.6640 (−15.20%) |
|
May 29, 2026
16d ago
|
S-3
| $0.7920 $0.7830 | ▲ +1.14% | ▲ +1.28% | $0.6640 (+16.16%) |
|
May 15, 2026
4w ago
|
8-K
| $0.8290 $0.8280 | ▼ −0.12% | ▲ +0.53% | $0.6640 (−19.90%) |
|
Mar 3, 2026
14w ago
|
EFFECT
| $1.06 $1.09 | ▲ +2.83% | ▲ +2.07% | $0.6640 (−37.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access